Valproic acid-exposed astrocytes impair inhibitory synapse formation and function

被引:0
作者
Kotomi Takeda
Takuya Watanabe
Kohei Oyabu
Shuntaro Tsukamoto
Yuki Oba
Takafumi Nakano
Kaori Kubota
Shutaro Katsurabayashi
Katsunori Iwasaki
机构
[1] Fukuoka University,Department of Neuropharmacology, Faculty of Pharmaceutical Sciences
[2] Fukuoka University,A.I.G. Collaborative Research Institute for Aging and Brain Sciences
[3] Fukuoka University,Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Valproic acid (VPA) is widely prescribed to treat epilepsy. Maternal VPA use is, however, clinically restricted because of the severe risk that VPA may cause neurodevelopmental disorders in offspring, such as autism spectrum disorder. Understanding the negative action of VPA may help to prevent VPA-induced neurodevelopmental disorders. Astrocytes play a vital role in neurodevelopment and synapse function; however, the impact of VPA on astrocyte involvement in neurodevelopment and synapse function has not been examined. In this study, we examined whether exposure of cultured astrocytes to VPA alters neuronal morphology and synapse function of co-cultured neurons. We show that synaptic transmission by inhibitory neurons was small because VPA-exposed astrocytes reduced the number of inhibitory synapses. However, synaptic transmission by excitatory neurons and the number of excitatory synapses were normal with VPA-exposed astrocytes. VPA-exposed astrocytes did not affect the morphology of inhibitory neurons. These data indicate that VPA-exposed astrocytes impair synaptogenesis specifically of inhibitory neurons. Our results indicate that maternal use of VPA would affect not only neurons but also astrocytes and would result in perturbed astrocyte-mediated neurodevelopment.
引用
收藏
相关论文
共 101 条
[1]  
Christensen J(2013)Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism JAMA 309 1696-1703
[2]  
Christensen J(2019)Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring JAMA Netw. Open 2 e186606-252
[3]  
Meador KJ(2013)Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study Lancet Neurol. 12 244-1009
[4]  
Kang J(2015)Suppression of NMDA receptor function in mice prenatally exposed to valproic acid improves social deficits and repetitive behaviors Front. Mol. Neurosci. 8 17-533
[5]  
Kim E(2015)Reduced adult hippocampal neurogenesis and cognitive impairments following prenatal treatment of the antiepileptic drug valproic acid Stem Cell Rep. 5 966-142
[6]  
Juliandi B(2000)Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models Environ. Health Perspect. 108 511-132
[7]  
Rice D(2014)Altered behavioral development in Nrf2 knockout mice following early postnatal exposure to valproic acid Brain Res. Bull. 109 132-1318
[8]  
Barone S(2008)VPA-induced apoptosis and behavioral deficits in neonatal mice Brain Res. 1023 126-147
[9]  
Fuenari MA(2018)Potentiation of glutamatergic synaptic transmission onto dorsal raphe serotonergic neurons in the valproic acid model of autism Front. Pharmacol. 9 1185-530
[10]  
Saw LC(2013)Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism Int. J. Neuropsychopharmacol. 16 1309-249